Thrombosis and Haemostasis, Inhaltsverzeichnis Thromb Haemost 1997; 78(01): 617-621DOI: 10.1055/s-0038-1657599 Bleeding and thrombosis in myeloproliferative disorders Schattauer GmbH Stuttgart Mechanisms of Bleeding and Thrombosis in Myeloproliferative Disorders Raffaele Landolfi 1 Centro Ricerche Fisiopatologia dell’Emostasi, Università Cattolica del Sacro Cuore, Roma , Roberto Marchioli 2 Dip. di Farmacologia Clinica ed Epidemiologia, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro , Carlo Patrono 3 Cattedra di Farmacologia I, Università degli Studi G. D’Annunzio, Chieti, Italy › Institutsangaben Artikel empfehlen Abstract als PDF herunterladen Artikel einzeln kaufen PDF (1002 kb) Referenzen References 1 Schafer AI. Bleeding and thrombosis in myeloproliferative disorders. Blood 1984; 64: 01-12 2 Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol/Hematol 1995; 20: 203-222 3 Michiels JJ, Abels J, Steketeee J, van Vliet H. Vuzeski KD: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med 1968; 122: 18-22 4 Michiels J, Koudstaal P, Mulder A, van Vliet H. Transient neurologic and ocular manifestation in primary thrombocythemia. Neurology 1993; 43: 1107-1110 5 Gruppo Italiano Studio Policitemia. Polycythemia Vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664 6 Silverstein M, Minn R. Primary or hemorrhagic thrombocythemia. Arch Int Med 1968; 122: 18-22 7 Marchioli R, Landolfi R, Barbui T, Tognoni G. Feasibility of randomized clinical trials in rare diseases: the case of polycythemia vera. Leukemia and Lymphoma 1996; 22: 121-127 8 Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk thrombosis. N Engl J Med 1995; 332: 1332-1336 9 Berk P, Goldberg J, Silverstein M. et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 19: 441-447 10 Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 1986; 23: 167-171 11 Watson KV, Key N. Vascular complications of essential thrombocythemia: a link to cardiovascular risk factors. Br J Haematol 1993; 83: 198-203 12 Tartaglia A, Goldberg JBerk, Wasserman L. Adverse effects of anti aggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176 13 Gruppo Italiano Studio Policitemia Vera. Low-dose aspirin in patients with polycythemia vera: a pilot study. Br J Haematol. in press 14 Pearson T, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia vera. Lancet 1978; 02: 1219-1223 15 van Genderen P, Michiels J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Press Med 1994; 23: 73-77 16 Landolfi R, Ciabattoni G, Patrignani P, Pogliani E, Castellana MAL, Bizzi B, Patrono C. Increased thromboxane A2 biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971 17 Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R. Increased Thromboxane Biosynthesis in Essential Thrombocythemia. Thromb Haemostas 1995; 74: 1225-1230 18 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376 19 Bazzan M, Tamponi G, Gallo E, Stella S, Schinco PC, Pannocchia A, Pileri A. Fibrinolytic imbalance in essential thrombocythemia: role of platelets. Haemostasis 1993; 23: 38-44 20 Cancelas JA, Garcia-Avello A, Garcia-Frade LJ. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 1994; 75: 513-520 21 Budde U, Schaefer G, Mueller N. et al. Acquired von Willebrand’s disease in the myeloproliferative disorders. Blood 1986; 64: 981-985 22 Budde U, Debt JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 1986; 68: 1231-1217 23 Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Haematol 1995; 48: 289-293 24 Jandrot-Perrus M, Clemetson KJ, Huisse M-G, Guillin MC. Thrombin interaction with platelet glycoprotein lb: effect of glycocalicin on thrombin specificity. Blood 1992; 80: 2781-2786 25 De CandiaE, De CristofaroR, De MarcoL, Mazzucato M, Picozzi M, Landolfi R. Thrombin interaction with platelet Glycoprotein lb: role of the heparin binding domain. Thromb. Haemostas. In press
